Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.
Optimi announces completion of three batches of its MDMA API manufactured from raw materials under the Company's Precursor Licence.
Optimi signs international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.
VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (Optimi or the Company), a Health Canada licensed drug researcher and...
Optimi Health Granted Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone (MDP2P), the precursor used in the chemical synthesis of MDMA.
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
Optimi Health Resolves Dispute
VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (œOptimi Health or the œCompany), a Canadian drug research and formulation...